

Curriculum Vitae

Menachem Mendel Shemtov, M.D.

Office Address: New York Presbyterian Hospital
Cornell University-Weill Medical College
Department of Urology
525 east 68th Street, Starr 912
New York, NY 10021

Office Phone: (212) 746-5449

Licensure: American Board of Urology Certification, March 2000
Diplomate, National Board of Medical Examiners
New York State Medical License, May 1991
DEA Certification

Appointments: Associate Professor of Clinical Urology August 2006 - Present
Associate Attending Urologist
New York Presbyterian Hospital
Cornell University-Weill Medical College

Associate Residency Director May 2000 - Present
Department of Urology
New York Presbyterian Hospital
Cornell University-Weill Medical College

Assistant Professor of Urology July 2000 - July 2006
Assistant Attending Urologist
New York Presbyterian Hospital
Cornell University-Weill Medical College

Instructor, Department of Urology July 1997- June 2000
Assistant Attending Urologist
New York Presbyterian Hospital
Cornell University-Weill Medical College

Attending, Consultative Services-Urology January 1998 - June 2003
Coler-Goldwater Memorial Hospital
Roosevelt Island, New York

Site Director, Primary Care Clerkship-Urology May 2000 – June 2004
New York Presbyterian Hospital
Cornell University-Weill Medical College

Consultant, Prostate Cancer Research May 2000 - December 2000
Strang Cancer Prevention Center

Education:

1985-1989 University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
Doctor of Medicine, 1989

- 1983-1984 Temple University
Philadelphia, Pennsylvania
Post-baccalaureate Premedical coursework
- 1980-1983 Rabbinical College of America
Morristown, New Jersey
Bachelor of Arts, 1983

Post Doctoral Training:

- 1995-1997 Fellow, Urologic Oncology
The New York Hospital-Cornell University Medical Center
New York, New York
- 1994-1995 Chief Resident, Urology
The Mount Sinai Medical Center
New York, New York
- 1991-1994 Resident, Urology
The Mount Sinai Medical Center
New York, New York
- 1989-1991 Intern and Resident, General Surgery
The Mount Sinai Medical Center
New York, New York

Professional Societies and Memberships:

American Urological Association, Active member
New York Section, American Urological Association

Awards:

First Prize, Laboratory Research
American Urological Association National Essay Contest: 1994

Honorable Mention, Laboratory-Formal Research
Ferdinand C. Valentine Essay Contest
New York Academy of Medicine: 1994

Second Prize, Laboratory-Formal Research
Ferdinand C. Valentine Essay Contest
New York Academy of Medicine: 1993

Active Protocols and Clinical Trials:

Development of the Cornell Prostate Cancer Biobank for the National Cancer Institute – Early Detection Research Network (NCI-EDRN) for Prostate Cancer Biomarker Research. Co-investigator, Weill Cornell Medical College IRB #0711009545

A Pilot Study of External Beam Radiation Therapy and Permanent Brachytherapy Using Cs-131 for Localized Prostate Carcinoma. Co-Investigator, Weill Medical College of Cornell University IRB #0511008207

A Prospective Study Evaluating Health Related Quality of Life (HRQOL) Following Robotic Prostatectomy for the Treatment of Localized Prostate Cancer: Comparison with Open Radical Prostatectomy. Co-Investigator, Weill Medical college of Cornell University IRB #0804-442

A Continuous Database of Patients with Prostate Cancer. Co-Investigator, Weill Medical College of Cornell University IRB #0804-441

Past Protocols and Clinical Trials:

Cryosurgery for Treatment of Prostate Cancer. Principal Investigator, Weill Medical College of Cornell University IRB # 0010004632

¹³¹I –Prost 30 for Treatment of Hormone Refractory Prostate Cancer. Co-Investigator, Weill Medical College of Cornell University IRB #0596-341

Phase I Trial of Monoclonal Antibody F31 in Renal Cancer. Co-Investigator, Weill Medical College of Cornell University IRB #0195-759

Subcutaneous IL-2 Plus Melatonin in Advanced Prostate Cancer. Co-Investigator, Weill Medical College of Cornell University IRB #0895-989

Adjuvant mAb Therapy in Localized, High Risk Prostate Cancer. Co-Investigator, Weill Medical College of Cornell University IRB# 0995-034

Publications:

Droller MJ and **Shemtov MM**: Quality of Life Issues in Late Stage Prostate Cancer. Controversies in the Management of Prostate Cancer, Part 6: 1991

Shemtov MM, Cheng DL, Shu W, Droller MJ and Liu BCS: LAK Cell Killing of Human T24 Bladder Cancer Cells Occurs Via Apoptosis: Possible Mechanism of Intravesical BCG Therapy. Surgical Forum 44:778-780, 1993

Shemtov MM, Cheng DL, Kong L, Sassoroli M, Droller MJ and Liu BCS: LAK Cell Mediated Apoptosis of Human Bladder Cancer Cells Involves a pH Dependent Endonuclease System in the Cancer Cell: Possible Mechanism of BCG Therapy. Journal of Urology 154:269-274, 1995.

Shemtov MM and Bander NH: Immunological Approaches to Genitourinary Malignancies. Campbell's Urology, Sixth Edition: Update, 1996.

Shemtov MM: Monoclonal Antibodies. AUA Update Series 1998; Vol XVII, Lesson 32.

Dasari N, Nori D, Vaughan ED, Parikh S, **Shemtov MM**, Allbright RM, Poli J, Presser J and Osian A: Positive Biopsies and Biochemical Outcome after Combined External Beam Radiation Therapy and Outpatient Conformal Brachytherapy for Clinically Localized Prostate Cancer. Radiology 225: 365-366, 2002.

Nori D, Reddy NMS, Vaughan ED and **Shemtov MM**: The Impact of Technological Advances on the Evolution of 3D Conformal Brachytherapy for Early prostate Cancer. Technology in Cancer Research and Treatment 3: 335-345, 2004.

Tewari A, Divine G, Chang P, **Shemtov MM**, Milowsky M, Nanus D and Menon M: Long Term Survival in Men With High Grade Prostate Cancer: A Comparison Between Conservative Treatment, Radiation Therapy and Radical Prostatectomy – A Propensity Scoring Approach. J Urology 177 (3): 911-5, 2007.

Schwartz MJ, Hwang DH, Hung AJ, Han J, McClain JW, **Shemtov MM**, Te AE, Sosa RE, Vaughan ED and Scherr DS: Negative Influence of Changing Biopsy Practice Patterns on the Predictive Value of Prostate Specific Antigen for Prostate Cancer. Cancer 112(8):1718-25, 2008.

Abstracts:

Shemtov MM, Cheng DL, Shu W, Droller MJ and Liu BCS: LAK Cell Killing of Human T24 Bladder Cancer Cells Occurs Via Apoptosis and Involves LAK Cell Membrane Fibronectin Molecule: Possible Mechanism of Intravesical BCG Therapy. (Abstract) Journal of Urology 149:271A, 1993.

Shemtov MM, Kong L, Cheng DL, Sassaroli M, Droller MJ, and Liu BCS: LAK Cell Mediated Apoptosis of Human Bladder Cancer Cells Involves a pH Dependent Endonuclease System in the Cancer Cell: Possible Mechanism of BCG Therapy. (Abstract) Journal of Urology 151:225A, 1994.

Stone NN, **Shemtov MM** and Thall E: Laparoscopic Orchiopexy of Intraabdominal Testis. (Videotape Abstract) Journal of Urology 151:225A, 1994.

Shemtov MM and Bander NH. Subcutaneous IL-2 Plus Melatonin in Advanced Prostate Cancer. Submitted American Urological Association Meeting, 1997.

Shemtov MM: Phase I/II Trial of Monoclonal Antibody (mAb) Prost 30 in Advanced Prostate Cancer. (Abstract) Journal of Urology 157:322A, 1997.

Dasari N, Nori D, Vaughan ED Jr., Parikh S, **Shemtov MM**, Poli JMR, Pressor J and Osian A. Role of Combined External Beam Radiation Therapy and Outpatient Conformal Brachytherapy for Clinically Localized Prostate Cancer. Submitted American Brachytherapy Society Meeting, 2001.

Dasari N, Nori D, Vaughan ED Jr., Parikh S, **Shemtov MM**, Poli JMR and Allbright RM. Percent Positive Biopsies and Biochemical Outcome After Combined External Beam Radiation Therapy and Outpatient Conformal Brachytherapy for Clinically Localized Prostate Cancer. American Society of Therapeutic Radiation Oncology, 2002.

Tewari A, Dasari R, El-Hakim A, Divine G, **Shemtov MM**, Porter CR, Gamito EJ, Schlegel PN, Menon M. High-grade Prostate Cancer: What is the Best Treatment Approach? (Abstract) Journal of Urology 2005; 173: 465A.

Hung AJ, Schwartz MJ, Hwang DH, McClain JW, Han J, **Shemtov MM**, Te AE, Sosa RE, Vaughan ED and Scherr DS. Changes in Practice Patterns and Outcomes of Transrectal Ultrasound Guided Prostate Biopsy. J Urology 177(4) 203A, 2007.

Tu JJ, Jhaveri JK, Yadav R, Leung RA, Te AE, Shemtov MM, et al. Cancer Control Outcomes Following Radical Prostatectomy. A Comparison Between Robotic and Open. Abstract #393. Accepted for Presentation During the 23rd Annual European Association of Urology Congress.

Invited Lectures and Presentations:

Voiding Dysfunction and BPH – Epidemiology, Evaluation and Non-surgical Therapy. Weill Cornell Medical College Men's Health Symposium, June 2009.

LAK Cell Killing of Human T24 Bladder Cancer Cells Occurs via Apoptosis: Possible Mechanism of Intravesical BCG Therapy (Podium). American College of Surgeons Annual Clinical Congress, 1993.

LAK Cell Killing of Human T24 Bladder Cancer Cells Occurs Via Apoptosis and Involves LAK Cell Membrane Fibronectin Molecule: Possible Mechanism of Intravesical BCG Therapy (Poster). American Urological Association Annual Meeting, 1993

LAK Cell Mediated Apoptosis of Human Bladder Cancer Cells Involves a pH Dependent Endonuclease System in the Cancer Cell: Possible Mechanism of Intravesical BCG Therapy (Podium). American Urological Association Annual Meeting, 1994.

October 1997: Visiting Professorship Salzburg Seminar, Salzburg, Austria

November 1997: What Every Man Should Know About Prostate Care: New York Hospital-Cornell University Medical College Health and Wellness Seminars.

Management of Testicular Cancer. New York Presbyterian Hospital – Weill Cornell Medical Center Department of Urology Basic Science Conference, December 1997.

Phase I/II Trial of Monoclonal Antibody Prost 30 in Advanced Prostate Cancer (Podium). American Urological Association Annual Meeting, 1997.

Cryotherapy for Initial or Recurrent Prostate Cancer: Us Too Prostate Cancer Survivor Support Group, February 2003.